ES2634260T3 - Métodos para tratar trastornos inmunitarios asociados a trasplante de injertos con moléculas de CTLA4 mutantes solubles - Google Patents

Métodos para tratar trastornos inmunitarios asociados a trasplante de injertos con moléculas de CTLA4 mutantes solubles Download PDF

Info

Publication number
ES2634260T3
ES2634260T3 ES06749324.7T ES06749324T ES2634260T3 ES 2634260 T3 ES2634260 T3 ES 2634260T3 ES 06749324 T ES06749324 T ES 06749324T ES 2634260 T3 ES2634260 T3 ES 2634260T3
Authority
ES
Spain
Prior art keywords
visit
mutant ctla4
regimen
mutant
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06749324.7T
Other languages
English (en)
Spanish (es)
Inventor
David Hagerty
James Rusnak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2634260T3 publication Critical patent/ES2634260T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Food Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ES06749324.7T 2005-04-06 2006-04-05 Métodos para tratar trastornos inmunitarios asociados a trasplante de injertos con moléculas de CTLA4 mutantes solubles Expired - Lifetime ES2634260T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66877405P 2005-04-06 2005-04-06
US668774P 2005-04-06
PCT/US2006/012648 WO2006108035A1 (en) 2005-04-06 2006-04-05 Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules

Publications (1)

Publication Number Publication Date
ES2634260T3 true ES2634260T3 (es) 2017-09-27

Family

ID=36694299

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06749324.7T Expired - Lifetime ES2634260T3 (es) 2005-04-06 2006-04-05 Métodos para tratar trastornos inmunitarios asociados a trasplante de injertos con moléculas de CTLA4 mutantes solubles

Country Status (25)

Country Link
US (2) US7482327B2 (enExample)
EP (1) EP1868635B1 (enExample)
JP (1) JP2008535841A (enExample)
KR (1) KR101235484B1 (enExample)
CN (1) CN101198347A (enExample)
AR (1) AR055052A1 (enExample)
AU (1) AU2006231622B2 (enExample)
BR (1) BRPI0608144A2 (enExample)
CA (1) CA2603970A1 (enExample)
CY (1) CY1119145T1 (enExample)
DK (1) DK1868635T3 (enExample)
EA (1) EA013122B1 (enExample)
ES (1) ES2634260T3 (enExample)
HR (1) HRP20171121T8 (enExample)
IL (1) IL186189A (enExample)
LT (1) LT1868635T (enExample)
ME (1) ME02930B (enExample)
MX (1) MX2007012222A (enExample)
NO (1) NO342966B1 (enExample)
NZ (2) NZ561655A (enExample)
PL (1) PL1868635T3 (enExample)
PT (1) PT1868635T (enExample)
RS (1) RS56138B1 (enExample)
SI (1) SI1868635T1 (enExample)
WO (1) WO2006108035A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
PL1868635T3 (pl) * 2005-04-06 2017-10-31 Bristol Myers Squibb Co Metody leczenia zaburzeń immunologicznych związanych z transplantacją narządów rozpuszczalnymi zmutowanymi cząsteczkami CTLA4
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
US7528111B2 (en) * 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
WO2008014035A2 (en) * 2006-07-25 2008-01-31 The Regents Of The University Of California Modulation of nkg2d and method for treating or preventing solid organ allograft rejection
CA2703263C (en) 2007-11-01 2014-03-18 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
WO2010098788A2 (en) * 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
WO2010049935A1 (en) * 2008-10-30 2010-05-06 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
WO2010132891A1 (en) * 2009-05-15 2010-11-18 The Board Of Trustees Of The Leland Stanford Junior University Combination therapy to inhibit t cell effector function
EP3053932B1 (en) * 2010-02-19 2020-07-22 Xencor, Inc. Novel ctla4-ig immunoadhesins
WO2011113019A2 (en) 2010-03-12 2011-09-15 Abbott Biotherapeutics Corp. Ctla4 proteins and their uses
ES2589678T3 (es) 2010-09-08 2016-11-15 Yeda Research And Development Co. Ltd. Uso de linfocitos T de memoria central anti-terceros para el tratamiento anti-leucemia/linfoma
EP2614083A2 (en) 2010-09-08 2013-07-17 Yeda Research and Development Co. Ltd An immunosuppressive drug combination for a stable and long term engraftment
SG11201400513PA (en) 2011-09-08 2014-06-27 Yeda Res & Dev Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
EA201591883A1 (ru) * 2013-03-28 2016-02-29 Бристол-Майерс Сквибб Компани Способы выявления пациентов, подверженных риску отторжения, резистентного к блокаде костимуляции
CN104673822A (zh) * 2013-11-27 2015-06-03 深圳先进技术研究院 一种重组载体及其制备方法和应用
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
US20170051059A1 (en) 2014-03-19 2017-02-23 Bristol-Myers Squibb Company Methods of treating transplant rejection using a domain antibody directed against cd40
MA41459A (fr) * 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
SMT202100467T1 (it) 2015-04-17 2021-09-14 Alpine Immune Sciences Inc Proteine immunomodulatorie con affinità regolabili
AU2016291825B2 (en) 2015-07-16 2022-08-11 Yeda Research And Development Co. Ltd. Genetically modified anti-third party central memory T cells and use of same in immunotherapy
AU2017248830B2 (en) 2016-04-15 2023-03-09 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
ES3064681T3 (en) 2017-01-18 2026-04-28 Yeda Res & Dev Genetically modified veto cells and use of same in immunotherapy
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
US10286036B2 (en) 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
EP3694870A1 (en) * 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
US11925640B2 (en) 2018-06-22 2024-03-12 Mayo Foundation For Medical Education And Research Methods and materials for improving arteriovenous fistula maturation and maintaining arteriovenous fistula functionality
WO2020010259A1 (en) * 2018-07-06 2020-01-09 Mayo Foundation For Medical Education And Research Methods and materials for improving transplant outcomes
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
US12202882B2 (en) 2020-05-08 2025-01-21 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
CN115089718B (zh) * 2021-11-30 2024-05-28 杭州瑞普晨创科技有限公司 用于异种移植的免疫抑制剂组合和免疫抑制方法
KR102929448B1 (ko) 2023-02-03 2026-02-26 이뮤노바이옴 주식회사 이식 거부 반응의 예방 또는 치료용 조성물
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
DE69226871T3 (de) 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
MXPA03006699A (es) * 2001-01-26 2004-05-31 Univ Emory Metodos de induccion de tolerancia al trasplante de organos y correccion de hemoglobinopatias.
ATE390931T1 (de) * 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
CA2482042A1 (en) 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
TWI328614B (en) 2002-12-23 2010-08-11 Bristol Myers Squibb Co Product quality enhancement in mammalian cell culture processes for protein production
EP1575998A4 (en) 2002-12-23 2007-07-25 Bristol Myers Squibb Co PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
PL1868635T3 (pl) * 2005-04-06 2017-10-31 Bristol Myers Squibb Co Metody leczenia zaburzeń immunologicznych związanych z transplantacją narządów rozpuszczalnymi zmutowanymi cząsteczkami CTLA4

Also Published As

Publication number Publication date
SI1868635T1 (sl) 2017-07-31
DK1868635T3 (en) 2017-09-11
BRPI0608144A2 (pt) 2009-11-17
US20100041602A1 (en) 2010-02-18
CA2603970A1 (en) 2006-10-12
MX2007012222A (es) 2007-12-06
PT1868635T (pt) 2017-07-27
IL186189A (en) 2015-11-30
US20070009511A1 (en) 2007-01-11
RS56138B1 (sr) 2017-10-31
AU2006231622A1 (en) 2006-10-12
HRP20171121T1 (hr) 2017-10-06
CY1119145T1 (el) 2018-02-14
CN101198347A (zh) 2008-06-11
EP1868635B1 (en) 2017-05-17
NZ561655A (en) 2010-01-29
EP1868635A1 (en) 2007-12-26
AR055052A1 (es) 2007-08-01
ME02930B (me) 2018-04-20
NO342966B1 (no) 2018-09-10
KR101235484B1 (ko) 2013-02-22
NZ576434A (en) 2010-06-25
WO2006108035A1 (en) 2006-10-12
PL1868635T3 (pl) 2017-10-31
EA013122B1 (ru) 2010-02-26
JP2008535841A (ja) 2008-09-04
LT1868635T (lt) 2017-07-10
NO20075078L (no) 2008-01-04
KR20070119728A (ko) 2007-12-20
IL186189A0 (en) 2008-01-20
US7482327B2 (en) 2009-01-27
AU2006231622B2 (en) 2012-07-05
HRP20171121T8 (hr) 2017-11-03
EA200702180A1 (ru) 2008-10-30

Similar Documents

Publication Publication Date Title
AU2018201273B2 (en) Fibronectin based scaffold domain proteins that bind to myostatin
ES2988351T3 (es) Anticuerpos dirigidos contra la proteína 3 de inmunoglobulina de linfocitos T y mucina (TIM-3)
ES2941965T3 (es) Nuevos receptores de linfocito T genomanipulados e inmunoterapias basadas en el uso de los mismos
AU2018209012B2 (en) BCMA-targeting antibody and use thereof
ES2565834T3 (es) Agentes de unión a receptor de Fc de región constante de inmunoglobulina
ES2784131T3 (es) Polipéptidos de unión beta del receptor PDGF
US11091559B2 (en) Anti-ALK antibodies and methods for use thereof
ES2531933T3 (es) Anticuerpos anti-NKG2A y usos de los mismos
KR101667096B1 (ko) 돌연변이 인터루킨-2 폴리펩티드
ES2719623T3 (es) Proteínas de fusión de fragmentos de proteínas humanas naturales para crear composiciones Fc de inmunoglobulina multimerizada de manera ordenada
CN107441480A (zh) 多肽及其作为用于治疗多发性硬化、类风湿性关节炎以及其他自身免疫病症的药物的用途
AU2024264749A1 (en) Compositions and methods for modulating lair signal transduction
TWI691510B (zh) 抗原結合分子和使用彼之方法
KR20160103134A (ko) 인터류킨-2 융합 단백질 및 이의 용도
RS63735B1 (sr) Himerni receptori i postupci njihove upotrebe
BRPI0706788A2 (pt) anticorpos antagonistas il-17
TW200819463A (en) Wnt antagonists and their use in the diagnosis and treatment of Wnt-mediated disorders
CN105873949A (zh) 新的抗baff抗体
JP2026053445A (ja) 抗ｃｄ２抗体
KR102453573B1 (ko) 항-pacap 항체
CN110366563A (zh) 抗lilrb3抗体及其使用方法
KR20200089282A (ko) 등장화제로서 라이신 염을 함유하는 아플리베르셉트 제제 및 그것의 용도
US20240247034A1 (en) Cystine knot scaffold platform
CN114901310A (zh) 使用il-2受体激动剂和免疫检查点抑制剂的组合疗法
JP2025522459A (ja) Ｋｒａｓ ｇ１２ｖ突然変異ポリペプチドを標的するｔ細胞受容体及びその用途